FDA Approves Lomitapide for Pediatric HoFH Treatment | Cardiology Today

Lomitapide Approved for Young Children with Rare Genetic Cholesterol Condition

The FDA has approved lomitapide capsules for the treatment of homozygous familial hypercholesterolemia (HoFH) in children as young as two years old, offering a new therapeutic option for a devastatingly rare genetic disease. The approval, announced March 5, 2026, expands the use of lomitapide – initially approved in 2012 for adults with HoFH – to a younger patient population facing significant cardiovascular risks. This decision comes less than a week after Rare Disease Day, highlighting a growing focus on addressing conditions affecting little numbers of individuals.

HoFH is an inherited condition characterized by extremely high levels of low-density lipoprotein (LDL) cholesterol, often referred to as “poor” cholesterol, from birth. Without treatment, individuals with HoFH typically experience premature cardiovascular disease, including heart attacks and strokes. The condition impacts as few as 1 in 360,000 people globally, according to Chiesi Global Rare Diseases, the manufacturer of lomitapide.

How Lomitapide Works and Its Place in Treatment

Lomitapide works by inhibiting microsomal triglyceride transfer protein (MTP), a protein crucial for the assembly of very low-density lipoprotein (VLDL) particles in the liver. By blocking MTP, lomitapide reduces the production of VLDL, which in turn lowers LDL cholesterol levels. It’s designed to be used in conjunction with a low-fat diet, regular exercise, and other lipid-lowering therapies, rather than as a standalone treatment.

The approval for pediatric use is based on data from the APH-19 trial, a phase 3, open-label, multicenter study published in The Lancet Diabetes & Endocrinology in 2024. The study enrolled 43 children and adolescents (median age 10.7 years, 56% female) already receiving standard lipid-lowering treatments. Results showed a significant reduction in LDL cholesterol levels of 53.5% at week 24 (95% confidence interval, 61.6 to 45.4; P < .0001).

Beyond LDL, the trial as well demonstrated reductions in non-HDL cholesterol (53.9%), total cholesterol (50%), very LDL (50.2%), apolipoprotein B (52.4%), triglycerides (49.9%), and lipoprotein(a) – though the effect on lipoprotein(a) varied depending on how it was measured (mg/dL vs. Nmol/L).

Trial Details and Considerations

The APH-19 trial’s open-label design – meaning both researchers and participants knew who was receiving the treatment – introduces a potential for bias. While the observed reductions in lipid levels are promising, it’s vital to note that the study did not include a placebo control group. This makes it difficult to definitively attribute the observed changes solely to lomitapide, as other factors, such as dietary changes or increased physical activity, could have contributed.

Adverse events reported in the trial were generally mild and related to the gastrointestinal and hepatic systems. However, the long-term safety and efficacy of lomitapide in children remain to be fully established, and ongoing monitoring will be crucial.

What This Means for Families and Clinicians

“Children with HoFH face extraordinary challenges from the moment they’re diagnosed,” said Katherine Wilemon, founder and CEO of Family Heart Foundation, in a press release. “Their lives are shaped by frequent medical visits and the constant worry of cardiovascular risk at an age when most kids are just learning to ride a bike or play sports. The recent treatment approval for this age group marks a meaningful step forward for young children impacted by HoFH.”

The availability of lomitapide for younger patients offers a potential to improve their long-term cardiovascular health and quality of life. However, clinicians will need to carefully weigh the benefits and risks of treatment on an individual basis, considering the child’s overall health status and response to other therapies.

Ongoing Research and Future Directions

While lomitapide represents a significant advance, research continues to explore other potential therapies for HoFH. Recent studies have investigated the use of PCSK9 inhibitors, such as alirocumab, and evinacumab, another novel lipid-lowering agent, in patients with HoFH. Research published in 2020 demonstrated that both alirocumab and evinacumab can significantly reduce LDL cholesterol levels in these patients.

gene therapy approaches are being investigated as potential curative treatments for HoFH, aiming to correct the underlying genetic defect responsible for the condition.

Navigating the Complexities of Lipid Management in Pregnancy

It’s important to note that managing high cholesterol, particularly during pregnancy, presents unique challenges. Many lipid-lowering medications lack sufficient safety data for use in pregnant or lactating women. Recent guidance highlights the need for careful consideration and individualized treatment plans in these cases, with emerging data suggesting statins may be safe for some pregnant women at high risk for cardiovascular events.

The FDA approval of lomitapide for children with HoFH underscores the importance of continued research and development of therapies for rare genetic diseases. As our understanding of these conditions evolves, You can expect to witness further advancements in treatment options and improved outcomes for affected individuals and their families.